Get the Stockscreener App
10.12
0.10%
0.010
After Hours:
10.32
0.20
+1.98%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $10.12, with a volume of 12.73M.
It is up +0.10% in the last 24 hours and down -0.20% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$10.11
Open:
$10.085
24h Volume:
12.73M
Relative Volume:
1.30
Market Cap:
$11.80B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.1924
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
-2.32%
1M Performance:
-0.20%
6M Performance:
+17.67%
1Y Performance:
-23.22%
1-Day Range:
$9.92
$10.16
1-Week Range:
$9.92
$10.95
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.12 | 11.67B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
120.24 | 52.69B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.66 | 43.09B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.90B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
23.97 | 28.06B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
448.91 | 19.55B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Using AI based signals to follow Viatris Inc.July 2025 PreEarnings & Risk Controlled Daily Trade Plans - newser.com
What technical charts say about Viatris Inc. stock2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - newser.com
Viatris Inc. (NASDAQ:VTRS) Q3 2025 Earnings Call Transcript - Insider Monkey
Viatris Nears Completion Of Company-Wide Strategic Review - Citeline News & Insights
Is it time to cut losses on Viatris Inc.Risk Management & Precise Buy Zone Tips - newser.com
Is now a turning point for Viatris Inc.Portfolio Value Summary & AI Forecasted Stock Moves - newser.com
Viatris Lifts Forecasts After Branded Drug Sales Outpace Estimates - Finimize
Viatris Inc. Reports Steady Q3 2025 Performance - TipRanks
Viatris, Inc. Earnings Call: Mixed Sentiment and Strategic Focus - TipRanks
Viatris: Q3 Earnings Snapshot - Stamford Advocate
3rd Circ. Won't Revive Investors' Suit Over Viatris Sale - Law360
Viatris (VTRS) Q3 2025 Earnings Call Transcript - Fortune
Can volume confirm reversal in Viatris Inc.Trade Analysis Report & Expert Approved Momentum Ideas - newser.com
Viatris Outpaces Expectations And Lifts Guidance After New Deal - Finimize
Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs - MSN
Viatris Q3 2025 presentation slides: Raises full-year guidance despite GAAP losses By Investing.com - Investing.com South Africa
Viatris Q3 2025 presentation slides: Raises full-year guidance despite GAAP losses - Investing.com
Earnings call transcript: Viatris Q3 2025 beats earnings expectations, stock dips - Investing.com India
Needle-Free Devices, Technologies and Global Markets (2025-2030) Featuring Profiles of GSK, Novartis, Viatris, PharmaJet and Other Key Players - Yahoo Finance
Viatris Investors Lose Bid to Revive Biosimilars Spinoff Suit - Bloomberg Law News
Viatris Shows Improved Relative Strength; Still Shy Of Benchmark - MSN
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance - Nasdaq
Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance - AlphaStreet
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Viatris raises outlook as emerging markets drive Q3 beat - MSN
Viatris Inc. Seeks M&A Opportunities - MarketScreener
Viatris raises 2025 outlook after Q3 beat (VTRS:NASDAQ) - Seeking Alpha
Viatris Reports Strong Q3 2025 Financial Results - TipRanks
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates - Yahoo! Finance Australia
(VTRS) Viatris Expects Full Year 2025 Adjusted EPS Range $2.25$2.35, vs. FactSet Est of $2.29 - MarketScreener
(VTRS) Viatris Expects Full Year 2025 Revenue Range $13.90B$14.30B, vs. FactSet Est of $13.94B - MarketScreener
Viatris Q3 Adjusted Earnings Fall, Revenue Rises; Raises 2025 Guidance - MarketScreener
Earnings Flash (VTRS) Viatris Inc. Reports Q3 Revenue $3.76B, vs. FactSet Est of $3.62B - MarketScreener
Earnings Flash (VTRS) Viatris Inc. Posts Q3 Adjusted EPS $0.67 per Share, vs. FactSet Est of $0.62 - MarketScreener
Viatris earnings beat by $0.05, revenue topped estimates - Investing.com
Viatris’s (NASDAQ:VTRS) Q3 Sales Top Estimates - Yahoo Finance
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance - The AI Journal
Viatris : VTRS Q3 2025 Earnings PresentationFINAL - MarketScreener
Viatris Q3 revenue and adjusted EPS beat estimates, helped by Aculys Pharma acquisition - TradingView
Viatris Inc. stock outlook for YEAR2025 Market Outlook & Risk Managed Investment Signals - newser.com
United States Lipodystrophy Market 2025: Industry - openPR.com
Can Viatris Inc. (VIA) stock surprise markets with earningsWeekly Gains Summary & Smart Investment Allocation Tips - newser.com
Can Viatris Inc. stock continue upward trendRate Hike & Daily Profit Focused Screening - fcp.pa.gov.br
How Viatris Inc. stock trades during market volatilityCPI Data & Step-by-Step Swing Trade Plans - fcp.pa.gov.br
Is Viatris Inc. (VIA) stock overpriced at current multiples2025 Top Gainers & High Win Rate Trade Tips - newser.com
Why Viatris Inc. stock could be next big winnerEarnings Beat & Free Daily Entry Point Trade Alerts - fcp.pa.gov.br
Will Viatris Inc. stock go up soon2025 Market Overview & Community Consensus Stock Picks - newser.com
Will Viatris Inc. stock reach Wall Street targetsEarnings Summary Report & Community Trade Idea Sharing - newser.com
Will Viatris Inc. stock benefit from upcoming earnings reports2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - newser.com
Will Viatris Inc. stock recover faster than peersMarket Activity Report & Technical Confirmation Trade Alerts - newser.com
What makes Viatris Inc. (VIA) stock appealing to growth investorsBear Alert & Low Risk Investment Opportunities - fcp.pa.gov.br
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):